First experiences with the stable prostacyclin analog iloprost in the evaluation of heart transplant candidates with increased pulmonary vascular resistance  by Sablotzki, Armin et al.
Standard open repair allowed the evacuation of the huge he-
matoma in the retroperitoneal space that was responsible for com-
partment syndrome leading to ischemic colitis.
Our experience is limited to one successful case, and no defin-
itive conclusions can be reached concerning the choice of 1-stage
surgery combining off-pump CABG and open repair of the rup-
tured aneurysm.
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First experiences with the stable prostacyclin analog iloprost in the
evaluation of heart transplant candidates with increased pulmonary
vascular resistance
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An increased pulmonary vascular resistance (PVR) isdescribed as a predictor of increased mortality afterorthotopic heart transplantation. The measurement ofpulmonary hemodynamics is a routine procedure in
the assessment of potential transplant recipients because the infor-
mation about the response to vasodilator therapy is of great interest
for the postoperative management of right-heart failure.1
The therapeutic limitation of intravenous vasodilators is the
systemic vasodilation and hypotension. Inhaled nitric oxide (NO)
and prostacyclin (PGI2) have been shown to act as selective
pulmonary vasodilators without systemic effects in patients with
primary and secondary pulmonary hypertension as well.2 Unfor-
tunately, NO is a toxic molecule and requires specialized delivery
systems and monitoring. Because of its short half-life, NO has to
be administered continuously, and even brief interruptions can
cause a dangerous rebound of pulmonary hypertension. Inhaled
PGI2 shows advantages because of the lack of toxic reactions but
no improved effects on hemodynamics.2 Hoeper and colleagues3
described the use of aerosolized iloprost for severe pulmonary
hypertension. Iloprost has a plasma half-life of 20 to 30 minutes
and induces pulmonary vasodilation that persists for about 2 to 4
hours. It might also exert systemic circulatory effects because the
molecule spills over into the systemic circulation. In patients with
primary pulmonary hypertension, iloprost was more potent than
inhaled NO.
Currently, there is no information about the use of iloprost in
patients with secondary pulmonary hypertension caused by
chronic cardiac failure. The aim of the present study was to
compare the hemodynamic effects of inhaled NO and inhaled
aerosolized iloprost in heart transplant candidates with increased
pulmonary hypertension.
Patients and Methods
Twenty male patients (age, 52.8  5.8 years) with increased PVR
(266.7  78 dynes  s1  cm5) scheduled for diagnostic right-
heart catheterization were included after providing informed con-
sent. The diagnoses were ischemic (n  11) or dilated (n  9)
cardiomyopathy. Measurement of hemodynamics (mean arterial
pressure, mean pulmonary artery pressure [MPAP], systemic vas-
cular resistance [SVR], and pulmonary vascular resistance [PVR])
was performed by using a radial artery catheter and a pulmonary
artery catheter. All parameters were determined at baseline and at
the end of each evaluation period. Triplicate measurements were
averaged for each reported cardiac output.
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During the whole study period, the patients were breathing
medical air and oxygen in an inspiratory concentration of 25%
through a tight-fitting face mask with a nonrebreathing circuit. NO
was administered through a T piece in an inspiration-triggered
modus to the inspiratory limb of the breathing device. The NO
concentration was measured with a chemoluminometer.
After inhaling NO in concentrations of 5, 10, and 30 ppm, a
complete evaluation of hemodynamics was performed. Thereafter,
NO was discontinued, and after 20 minutes of washout, new basic
hemodynamics were obtained before the inhalation of iloprost
(Ilomedin; 50 g diluted in 3 mL of isotone saline solution) was
started. Another hemodynamic measurement followed 5 minutes
after the iloprost inhalation.
Results are expressed as mean values  SEM. Statistical anal-
ysis was made by using the nonparametric Friedman test, followed
by the Wilcoxon-Wilcox test. The relationship between initial
baseline PVR and MPAP levels and the effectiveness of both
treatments was tested with the Mann-Whitney U test. A P value of
less than .05 was considered to indicate statistical significance.
Results
All doses of NO and iloprost were well tolerated. There were no
significant effects of both NO and iloprost on mean arterial blood
pressure and SVR compared with baseline values. MPAP was
reduced by 10 and 30 ppm NO and iloprost, respectively (P .05).
Iloprost caused a greater decrease in MPAP compared with 10
ppm NO (24.7  2.3 vs 27.1  2.2 mm Hg, P  .05) and 30 ppm
NO (24.7  2.3 vs 27.7  2.2 mm Hg, P . 05). The PVR was
significantly reduced by 10 ppm NO and iloprost; the mean PVR
values with iloprost (172 16 dynes  s1  cm5) were lower than
with 10 ppm NO (216  26.3 dynes  s1  cm5), but differences
were not significant. Comparing the initial baseline levels of PVR
and MPAP with the effectiveness of both therapies, we found no
strong relationship (data not shown).
Conclusions
The use of NO, aerosolized PGI2, or both for evaluation of heart
transplant candidates with pulmonary hypertension has been de-
scribed previously,2,4 although the use of iloprost in those patients
has not been presented before. Haraldsson and associates4 de-
Figure 1. Influence of inhaled NO and iloprost on MPAP, mean arterial pressure (MAP), PVR, and SVR (n 20). Data
are expressed as means  SEM. *P < .05, **P <. 01 compared with baseline values.
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scribed a selective dose-dependent decrease in PVR at an inhaled
concentration of 10 g of PGI2 with no effects on systemic
circulation, but the effects of PGI2 and NO in view of the induction
of pulmonary vasodilation of heart transplant candidates were
comparable.2
In our study iloprost caused a significantly greater reduction in
MPAP and a tendency toward a greater decrease of PVR than NO.
This effect was not accompanied by a reduction of mean arterial
pressure or SVR compared with baseline values or compared with
values with NO. The main disadvantage of NO inhalation was an
increase in MPAP and PVR in 4 (28.6%) patients. This observa-
tion is nearly identical with the experience of Hoeper and cowork-
ers,3 who reported an increase of MPAP in 23% and an increase of
PVR in 31%, respectively, while using comparable concentrations
of NO. By contrast, none of our patients treated with iloprost had
an increase in MPAP, PVR, or both.
Our study has several limitations. First, the chosen concentra-
tions of NO might not have caused a maximum of vasodilation in
all patients, but other studies have demonstrated that maximum
effects on MPAP were achieved with NO concentrations of be-
tween 10 and 20 ppm and that higher concentrations could not
improve the effectiveness of NO.5 Furthermore, NO was given
before iloprost, and although we ensured that the hemodynamics
had returned to baseline before inhalation of iloprost, we can
not completely exclude a priming effect of pretreatment with
NO.
The results of our study show that inhaled aerosolized iloprost
induces a reliable hemodynamic response in the evaluation of heart
transplant candidates with increased PVR. Compared with the
effects of inhaled NO, iloprost was more effective in reducing
pulmonary artery pressure. Further advantages of iloprost inhala-
tion are the lack of adverse reactions and an ease of administration.
Because of these facts, we recommend iloprost as a routine screen-
ing drug for vascular reactivity, and we recommend further com-
parative studies to evaluate the place of iloprost in the management
of perioperative pulmonary hypertension in cardiac transplantation
in the near future.
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